1-9 of 9
Bernd L. Hartmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Lisa Pleyer, Marc Vaisband, Patrick Klammer, Manuel Drost, Hubert Angermann, Felix Keil, Verena Petzer, Sonja Heibl, Jennifer Moritz, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd L. Hartmann, Gregor Aschauer, Clemens Schmitt, Sonia Vallet, Szilvia Boros, Petra Pichler, Andrea Hammerl-Steiner, Felix Renneberg, Dilyan Majjiga, Gudrun Russ, Alexander Egle, Michael Leisch, Thomas Melchardt, Nadja Zaborsky, Viktoria Faber, Jan Philipp Bewersdorf, Amer M. Zeidan, Jan Hasenauer, Richard Greil
Journal: Blood
Blood (2024) 144 (Supplement 1): 7511.
https://doi.org/10.1182/blood-2024-208073
Published: 2024
Journal Articles

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Lisa Pleyer, Patrick Klammer, Manuel Drost, Hubert Angermann, Felix Keil, Verena Petzer, Sonja Heibl, Jennifer Moritz, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd L. Hartmann, Gregor Aschauer, Clemens Schmitt, Sonia Vallet, Szilvia Boros, Petra Pichler, Andrea Hammerl-Steiner, Felix Renneberg, Susanne Schnabel, Dilyan Majjiga, Thomas Melchardt, Alexander Egle, Michael Leisch, Richard Greil
Journal: Blood
Blood (2024) 144 (Supplement 1): 3793.
https://doi.org/10.1182/blood-2024-207230
Published: 2024
Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Lisa Pleyer, Marc Vaisband, Michael Pfeilstocker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd L. Hartmann, Andreas Petzer, Martin Schreder, Clemens A. Schmitt, Sonia Vallet, Thomas Melchardt, Lukas Scagnetti, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Jan Hasenauer, Richard Greil
Journal: Blood
Blood (2022) 140 (Supplement 1): 1346–1349.
https://doi.org/10.1182/blood-2022-168521
Published: 2022
Journal Articles

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Wolfgang Willenbacher, Petra Pichler, Irene Strassl, Maria-Theresa Krauth, Hermine Agis, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Roman Weger, Ella Willenbacher
Journal: Blood
Blood (2022) 140 (Supplement 1): 13194–13195.
https://doi.org/10.1182/blood-2022-165366
Published: 2022
Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Niklas Zojer, Johannes Andel, Bernd L. Hartmann, Christoph Tinchon, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Martin Schreder, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Michael Fillitz, Song-Yau Wang, Stefan Knop, Sarah Kainz, Bruno Paiva, Richard Greil
Journal: Blood
Blood (2022) 140 (Supplement 1): 10185–10188.
https://doi.org/10.1182/blood-2022-162336
Published: 2022
Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Irene Manrique, Richard Greil, Johannes Andel, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Alexander Egle, Andreas Petzer, Niklas Zojer, Eberhard Gunsilius, Reinhard Ruckser, Boris Bozic, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Martin Schreder, Song-Yau Wang, Wolfgang Willenbacher, Maria-Theresa Krauth, Christoph Tinchon, Michael Fillitz, Thomas Melchardt, Stefan Knop, Bruno Paiva, Heinz Ludwig
Journal: Blood
Blood (2021) 138 (Supplement 1): 1669.
https://doi.org/10.1182/blood-2021-150311
Published: 2021
Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Irene Manrique, PhD, Richard Greil, MD, Johannes Andel, MD, Siegfried Sormann, MD, Bernd L. Hartmann, MD, Klaus Podar, MDPhD, Alexander Egle, MD, Andreas Petzer, MD, Niklas Zojer, MD, Reinhard Ruckser, MD, Boris Bozic, MD, Clemens A. Schmitt, MD, Sigrid Machherndl-Spandl, MD, Hermine Agis, MD, Martin Schreder, MD, Maria-Theresa Krauth, MD, Christoph Tinchon, MD, Michael Fillitz, MD, Thomas Melchardt, MD PhD, Bruno Paiva, PhD, Heinz Ludwig, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-140918
Published: 2020
Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Heinz Ludwig, MD, Thomas Melchardt, MD PhD, Johannes Andel, MD, Eberhard Gunsilius, MD, Siegfried Sormann, MD, Axel Hinke, PhD, Bernd L. Hartmann, MD, Klaus Podar, MDPhD, Wolfgang Willenbacher, MD PhD, Alexander Egle, MD, Andreas Petzer, MD, Niklas Zojer, MD, Ewald Wöll, MD, Reinhard Ruckser, MD, Boris Bozic, MD, Clemens A. Schmitt, MD, Sigrid Machherndl-Spandl, MD, Maria-Theresa Krauth, MD, Martin Schreder, MD, Hermine Agis, MD, Christoph Tinchon, MD, Michael Fillitz, MD, Richard Greil, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–29.
https://doi.org/10.1182/blood-2020-140701
Published: 2020
Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Heinz Ludwig, MD, Siegfried Sormann, Niklas Zojer, Johannes Andel, Bernd L. Hartmann, Christoph Tinchon, MD, Eberhard Gunsilius, MD, Klaus Podar, MD PhD, Alexander Egle, MD, Wolfgang Willenbacher, MD PhD, Ewald Wöll, MD, Reinhard Ruckser, MD, Boris Bozic, MD, Maria-Theresa Krauth, MD, Andreas Petzer, MD, Clemens A. Schmitt, MD, Sigrid Machherndl-Spandl, MD, Hermine Agis, MD, Bruno Paiva, PhD, Richard Greil, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 696.
https://doi.org/10.1182/blood-2019-127954
Published: 2019